<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653444</url>
  </required_header>
  <id_info>
    <org_study_id>GC1119_P1</org_study_id>
    <nct_id>NCT01653444</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety and Exploratory Efficacy of GC1119</brief_title>
  <official_title>Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and exploratory efficacy of GC1119
      (recombinant human α-galactosidase A) for enzyme replacement therapy in Fabry disease
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>10weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change and %change of Plasma GL-3 concentration</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The ratio of subjects whose plasma GL-3 values are within reference range</measure>
    <time_frame>10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of urine GL-3 concentration</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of kidney function</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of kidney size</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change and %change of heart size</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of results of cornial opacity examination</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of scores that are measured by pain questionnaire</measure>
    <time_frame>baseline and 10weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Fabry Disease</condition>
  <arm_group>
    <arm_group_label>GC1119 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg biweekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GC1119 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg biweekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC1119</intervention_name>
    <description>biweekly, IV infusion</description>
    <arm_group_label>GC1119 0.5 mg/kg</arm_group_label>
    <arm_group_label>GC1119 1.0 mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a current diagnosis of Fabry's disease

          -  Plasma α-gal activity of ≤ 1.5mnol/hr/ml and have a mutation in α-galactosidase A gene

          -  Males ≥ 16 years old

          -  Subjects capable of performing this clinical trial in an appropriate manner

          -  Informed consent form voluntarily signed by the subject(or his legally acceptable
             representative if the subject is under 20 years old) to participation in the study

          -  Agreement to contraception during the study period

        Exclusion Criteria:

          -  Serum creatinine &gt; 2.5mg/dl

          -  Subjects have a plan to kidney transplantation

          -  Subjects have undergone kidney transplantation

          -  Subjects are currently on dialysis

          -  Subjects have a clinically significant organic disease(cardiovascular, hepatic,
             pulmonary, neurologic, or renal disease)that in the opinion of the investigator would
             preclude participation in the trial

          -  Known life-threatening hypersensitivity(anaphylactic reaction) to α-galactosidase

          -  Treatment with another investigational product within 30days from the administration
             of study drug dosing or plans to be treated with another investigational product
             during the study period

          -  Known hypersensitivity to any of the ingredients of study drug(including excipients)

          -  Subjects need the medication of prohibited drug

          -  Alcoholism or drug addiction
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Songpa-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Cung Hyang University Hospital</name>
      <address>
        <city>Yongsan-gu</city>
        <state>Seoul</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University School of Medicine</name>
      <address>
        <city>Yeongtong-gu</city>
        <state>Suwon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

